Market Research Report
U.S. Orthobiologics Market Analysis - COVID19 - 2019-2025 - MedSuite - Includes: Bone Graft Substitutes, Cellular Allografts, Growth Factors, Orthopedic Cell Therapy, Hyaluronic Acid Viscosupplementation & Orthopedic Cartilage Repair Devices
|Published by||iData Research Inc.||Product code||1000911|
|Published||Content info||478 Pages
Delivery time: 1-2 business days
|U.S. Orthobiologics Market Analysis - COVID19 - 2019-2025 - MedSuite - Includes: Bone Graft Substitutes, Cellular Allografts, Growth Factors, Orthopedic Cell Therapy, Hyaluronic Acid Viscosupplementation & Orthopedic Cartilage Repair Devices|
|Published: March 19, 2021||Content info: 478 Pages||
Throughout this medical market research, the publisher analyzed 47+ Orthobiologics companies in the United States and utilized their comprehensive methodology to understand the Market Sizes, Unit Sales, ASPs, Company Market Shares, and to create accurate forecasts.
While this report suite report contains all of the U.S. Orthobiologics market analysis, each of the market segments is also available as a stand-alone a report, MedCore.
Overall, the U.S. orthopedic biomaterials market was valued at $3.1 billion in 2020. This is expected to increase over the forecast period to reach over $5 billion in 2025.
A particular trend in the U.S. orthopedic biomaterials market is competitors that are seeking to penetrate high-growth segments outside their traditional space by distributing existing products manufactured by other companies, rather than creating their own. This often involves partnering with a company by taking on the costs associated with regulation and market approval, in exchange for exclusive market rights. The distributor then pays the manufacturer in royalties. The goal is to penetrate the high-growth segments and build or strengthen networks before the segment matures. This is especially the case for competitors in segments that are in decline, such as competitors in the five-injection hyaluronic acid treatment.
Medtronic leads the U.S. orthopedic biomaterials market. They have the largest share in the bone graft substitute segment and had their dominating product, INFUSE™ in the growth factor market. This company's growth has been recovering since the negative media attention and lawsuits regarding off-label usage of its growth factor bone morphogenetic protein (BMP) product, INFUSE®, which accounts for a significant portion of the company's revenue in biologic therapy.